Thomas Diraimondo serves as Executive at Janux Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Thomas Diraimondo has executed 5 insider transactions totaling $266.1K, demonstrating a bearish approach to their equity position. Their most recent transaction on Jan 2, 2026 involved receiving (via award) 109,900 shares valued at $0.
Thomas Diraimondo currently holds 109,900 shares of Janux Therapeutics, Inc. (JANX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Thomas Diraimondo has been a net seller of JANX stock. They have purchased $0 and sold $266.1K worth of shares.
Thomas Diraimondo's most recent insider trade was on Jan 2, 2026, when they sold 109,900 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Jan 2, 2026 | JANX | $34.4K | Sale | 2,505 | $13.73 | Discretionary |
| Sep 27, 2024 | JANX | $31.9K | Sale | 675 | $47.22 | Planned |
| Sep 27, 2024 | JANX | $199.9K | Sale | 4,325 | $46.21 | Planned |